- $905.29m
- $995.23m
- $43.47m
- 52
- 80
- 77
- 80
Annual balance sheet for CorMedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 46.3 | 65.5 | 58.8 | 76 | 51.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.003 | 0.045 | 0 | — | 51.7 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 48.2 | 66.5 | 59.6 | 79.5 | 115 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.13 | 2.37 | 2.38 | 2.51 | 2.32 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 49.3 | 68.9 | 62 | 82.1 | 119 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.16 | 5.35 | 6.31 | 11.4 | 33.8 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.09 | 6.15 | 6.98 | 11.9 | 34.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 44.2 | 62.8 | 55.1 | 70.1 | 84.7 |
| Total Liabilities & Shareholders' Equity | 49.3 | 68.9 | 62 | 82.1 | 119 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |